Citalopram 20 mg tablets
Change in funded brand of citalopram from Arrow-Citalopram to PSM Citalopram
A decision has been made by PHARMAC to change the subsidised (funded) brand of citalopram from Arrow-Citalopram (supplied by Actavis) to PSM Citalopram, supplied by API Consumer Brands (“API”). The change will start to happen from 1 November 2015.
The information below may help to answer some questions you may have about this change.
Will the medicine work the same?
Your medicine itself is not changing, only the brand. The newly funded tablets contain the same amount of the active ingredients - citalopram. This means that the effect you experience when taking PSM Citalopram should be the same as the brand you are currently taking.
You shouldn’t notice any difference in how you feel after taking PSM-Citalopram. If you do notice any major changes or side effects, please talk with your doctor about it.
When will the change occur?
From 1 November 2015 PSM Citalopram will be listed on the Pharmaceutical Schedule, meaning that it will become funded
From 1 January 2016 a part payment may be required for the Arrow-Citalopram brand. To avoid this part payment, your pharmacist will need to dispense you PSM Citalopram.
From 1 April 2016 – only PSM Citalopram will be funded when you pick up your prescription from a community pharmacist. The Arrow-Citalopram brand may or may not be available after this date (at the discretion of the supplier, Actavis) and will not be funded.
Doctors and pharmacists have been kept informed about these changes and are the best people to discuss these changes with.
Will there be any additional costs for me to pay after 1 April 2016?
Other than the usual patient co-payment, there will be no extra cost for you to pay.
Will the tablets or pack look different?
Because they are made by a different supplier, the PSM Citalopram tablets and pack look a little different to your previous medication, but they will still have the same active medicine and should work just the same.
Why has this change happened?
Significant savings are associated with the move to the PSM Citalopram brand of citalopram tablets. This means that more money can be freed up to fund other medicines to treat other people in our communities. Rest assured, this medication has been approved by Medsafe, New Zealand’s medicines regulator.
Where can I get more information?
If you have any concerns about the changes please contact PHARMAC Enquiries at email@example.com or telephone the helpdesk on FREE phone 0800 660 050 between 9am and 5pm Monday to Friday.
Your health professional will also help guide you during the changeover period.
Last updated: 26 October 2017